Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia
Sponsor: Novartis Pharmaceuticals
Summary
This study is an open label, randomized, prospective, type I hybrid effectiveness- implementation, pragmatic clinical trial to evaluate the impact of a targeted lipid optimization program on LDL-C control in participants with dyslipidemia who are at high risk or very high risk of cardiovascular events.
Official title: A Prospective, Type I Hybrid Effectiveness-implementation, Open Label, Randomized Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in at- Risk Adult Patients From Abu Dhabi, United Arab Emirates (UAE) With Dyslipidemia
Key Details
Gender
All
Age Range
18 Years - 100 Years
Study Type
INTERVENTIONAL
Enrollment
326
Start Date
2025-11-26
Completion Date
2027-06-30
Last Updated
2026-01-30
Healthy Volunteers
No
Conditions
Interventions
Educational Material
Health Education Intervention delivered via clinic visits (every 4 months) and virtual sessions (between each clinic visit)
Standard of care
Standard of care
Locations (1)
Novartis Investigative Site
Abu Dhabi, United Arab Emirates